Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors.
about
Histone Deacetylases and Cardiometabolic DiseasesSignaling effectors underlying pathologic growth and remodeling of the heartOxidative stress and epigenetic regulation in ageing and age-related diseasesTherapeutic efficacy of valproic acid in a combined monocrotaline and chronic hypoxia rat model of severe pulmonary hypertensionEmerging roles for histone deacetylases in pulmonary hypertension and right ventricular remodeling (2013 Grover Conference series)Acetyl-lysine erasers and readers in the control of pulmonary hypertension and right ventricular hypertrophyAll-trans retinoic acid and sodium butyrate enhance natriuretic peptide receptor a gene transcription: role of histone modificationMicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblastsVascular histone deacetylation by pharmacological HDAC inhibition.Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes.Identification of selective class II histone deacetylase inhibitors using a novel dual-parameter binding assay based on fluorescence anisotropy and lifetime.Non-histone lysine acetylated proteins in heart failureClass II HDAC inhibition hampers hepatic stellate cell activation by induction of microRNA-29Long-term administration of the histone deacetylase inhibitor vorinostat attenuates renal injury in experimental diabetes through an endothelial nitric oxide synthase-dependent mechanismThree 4-letter words of hypertension-related cardiac hypertrophy: TRPC, mTOR, and HDAC.Targeting inflammation in heart failure with histone deacetylase inhibitors.Cardiac HDAC6 catalytic activity is induced in response to chronic hypertensionEmergence of fibroblasts with a proinflammatory epigenetically altered phenotype in severe hypoxic pulmonary hypertensionHistone/protein deacetylases control Foxp3 expression and the heat shock response of T-regulatory cells.Treatment of chronic kidney diseases with histone deacetylase inhibitors.Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes.Metabolism as a key to histone deacetylase inhibition.Non-sirtuin histone deacetylases in the control of cardiac agingValproic acid attenuates proteinuria and kidney injury.Mitochondria and Oxidative Stress in the Cardiorenal Metabolic Syndrome.Inhibition of Histone Deacetylase Activity Aggravates Coxsackievirus B3-Induced Myocarditis by Promoting Viral Replication and Myocardial Apoptosis.Histone deacetylase inhibitors attenuate P-aIgA1-induced cell proliferation and extracellular matrix synthesis in human renal mesangial cells in vitro.Reciprocal regulation of RORγt acetylation and function by p300 and HDAC1.Integrating molecular genetics and systems approaches to pulmonary vascular diseases.Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism.Signal-dependent repression of DUSP5 by class I HDACs controls nuclear ERK activity and cardiomyocyte hypertrophy.HDAC inhibitors in kidney development and disease.Retinoic acid and sodium butyrate suppress the cardiac expression of hypertrophic markers and proinflammatory mediators in Npr1 gene-disrupted haplotype mice.Histone deacetylase inhibitor, CG200745, attenuates cardiac hypertrophy and fibrosis in DOCA-induced hypertensive rats.Acetylation of cyclophilin A is required for its secretion and vascular cell activationHistone deacetylase inhibitors modulate the transcriptional regulation of guanylyl cyclase/natriuretic peptide receptor-a gene: interactive roles of modified histones, histone acetyltransferase, p300, AND Sp1Kidney and heart interactions during cardiorenal syndrome: a molecular and clinical pathogenic framework.Anticipated classes of new medications and molecular targets for pulmonary arterial hypertensionChromatin modifications remodel cardiac gene expression.Chromatin dynamics in kidney development and function.
P2860
Q26800062-9045837F-E295-48C4-9B53-56D1D300CD25Q26825154-9191DB8F-8A48-40FF-8877-B66538CED180Q26991587-5BF7CDAF-0644-4D7C-9A95-E8A60D886B68Q27316522-E6D7D510-8B27-4231-9BF2-F54EC96FE6B7Q28082797-537D9BE9-0848-4370-8011-E8703D440CBDQ28084598-84C8C7D4-5C2C-4983-9EC5-22630B3EA9FDQ33584601-1B47DB77-C017-4C73-B44D-4EC5F2ABD774Q33982509-42416020-75AB-4DDB-8458-F63308F47CF5Q33994818-8E83A235-1758-46B0-9473-0EC449007C69Q33998649-45BAB06A-342A-4277-8FE4-81A3119C1E20Q34057844-7FB73B82-B995-4666-A110-E58BE24F8017Q34095772-6DAC1BA2-6661-445A-9C0D-02EFF29C0438Q34576966-0CD5AA28-CE20-49A5-A764-53F42B8156EBQ34839640-CF708DE8-AE08-46EE-982B-0D835171E1BFQ34969926-572B8FA8-1B7C-40EF-9252-794F75DEC952Q35016989-6DDE4DAF-7CC5-4D44-8DDF-FE7FD95B156EQ35040811-F7188165-A09E-4A26-8EFE-738CA6298845Q35175427-5522B38E-50B6-417C-ACA4-F2F30B93F134Q35300659-A6C13F2C-62F7-42E0-904E-9C7F68EEFF35Q35545347-0CEE909E-44BB-4D89-8F76-4D4C79C35E45Q35597103-F210C53B-9944-4AB8-BAF4-336E2ECE3AEEQ35661981-FD844530-FBF6-4991-8FCC-849C4A3079A2Q35695849-0CE94BAA-F73F-4E80-AB72-92F4AEB8A6B6Q35758297-967D24CB-A48B-4295-9BF4-A8899AA59850Q35976043-BCFFBA55-5191-4DC7-A288-49B385AB5DC4Q36086324-B8D1405B-ECDD-473E-8BF9-9FFAA50AC026Q36579290-727FEB94-6747-4155-B544-7AC404A6D980Q36756039-408C1E2F-A2AF-4D3F-8347-44DB393A745AQ36810797-16BDBACF-762E-4D6C-86C0-88F08AEAEB3BQ36929766-81121897-2BB0-4CBB-B57D-C1A1E762C455Q36932490-7411238D-2B53-4935-828C-8501960A12C0Q37115414-58EC5CE4-DCFA-47CA-9965-9F03C2D61595Q37139674-1EAB9F28-417C-45DA-ABD2-A64CA071AF34Q37239770-B24C0F45-DB78-44E3-AFD6-EE1429FD1842Q37591224-0832AE3C-8802-46C3-8589-C77FC58E5ECFQ37622637-B426DD97-887B-497D-B7D8-9C9BE90C6159Q37907323-F0AF7897-79B5-431A-BA3A-101E0AF63085Q38105550-8337FFAF-C1F1-4A43-8EF0-0EDE7A64D7C6Q38210525-2869DA03-70B0-4629-9A57-A205488521BFQ38210944-61F9D0DA-A689-4F67-AEB4-CDD26F01849F
P2860
Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Protein acetylation in the car ...... istone deacetylase inhibitors.
@en
Protein acetylation in the car ...... istone deacetylase inhibitors.
@nl
type
label
Protein acetylation in the car ...... istone deacetylase inhibitors.
@en
Protein acetylation in the car ...... istone deacetylase inhibitors.
@nl
prefLabel
Protein acetylation in the car ...... istone deacetylase inhibitors.
@en
Protein acetylation in the car ...... istone deacetylase inhibitors.
@nl
P1433
P1476
Protein acetylation in the car ...... istone deacetylase inhibitors.
@en
P2093
Erik W Bush
Timothy A McKinsey
P304
P356
10.1161/CIRCRESAHA.109.209338
P577
2010-02-01T00:00:00Z